Drug Discovery · Frederiksberg, Denmark · Founded 2017 · Privately Held (backing)
Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. Adcendo is based in Frederiksberg, Denmark and was founded in 2017. It was valued at $210 million at its later-stage round in Nov 2024, the last priced event on record. It has raised $316 million across 2 recorded rounds; the latest was a $134 million Series B in Nov 2024.
PMV mark · valuation
$209.9M
Oct 2026
Priced at
its later-stage round
Nov 2024
Total raised
$315.9M
Last round
Later Stage VC (Series B)
Nov 2024
Team — not yet on record
No current team members for Adcendo are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Adcendo with a free account
·The complete investor list: 21 names
·Watch Adcendo: the Monday email on marks, rounds and moves
